Suppr超能文献

α-降钙素基因相关肽在心血管系统调节中的功能作用。

Functional role of alpha-calcitonin gene-related peptide in the regulation of the cardiovascular system.

作者信息

Shen Y T, Pittman T J, Buie P S, Bolduc D L, Kane S A, Koblan K S, Gould R J, Lynch J J

机构信息

Department of Pharmacology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

出版信息

J Pharmacol Exp Ther. 2001 Aug;298(2):551-8.

Abstract

It remains unknown whether the extent of vasoactive response to exogenous calcitonin gene-related peptide (CGRP) varies among different regional vascular beds. It is also unclear whether endogenous CGRP plays a functional role in regulating basal vascular activity. To address these two issues, experiments were conducted in 27 anesthetized rats instrumented with a carotid flow probe and catheters in a jugular vein, left ventricle (LV), and femoral artery, and in 6 conscious dogs, chronically instrumented with LV pressure gauge, aortic and atrial catheters, and ascending aortic, coronary, carotid, and renal flow probes. In both species, administration of human alpha-CGRP (0.1-0.5 microg/kg, i.v.) induced a dose-dependent peripheral vasodilation that was completely abolished by pretreatment with alpha-CGRP[8-37] (30 microg/kg/min, i.v.), a competitive antagonist of CGRP receptors. Regional blood flow measured by the radioactive microsphere technique in rats showed that the alpha-CGRP (0.3 microg/kg, i.v.)-induced increase in blood flow was greater (p < 0.05) in the heart (+53 +/- 16%) than in the brain (+14 +/- 6%). In the presence of beta-adrenergic receptor blockade with propranolol, however, the increases in blood flow in these two vascular beds were identical. In conscious dogs, alpha-CGRP (0.3 microg/kg, i.v.) produced similar increases in coronary (+24 +/- 6%), carotid (+26 +/- 3%), and renal (+26 +/- 6%) blood flow, which were different from the patterns induced by other vasodilators; at an equivalent level of reduction in mean arterial pressure and total peripheral resistance, alpha-CGRP increased coronary and carotid blood flow significantly less (p < 0.05) than adenosine or nitroprusside. Unlike alpha-CGRP, adenosine and nitroprusside, as expected, induced pronounced differential blood flow changes in these vascular beds. Neither systemic hemodynamics nor regional blood flow distribution was altered by the administration of a pharmacological blocking dose of alpha-CGRP[8-37] in the two species. Thus, we conclude that endogenous alpha-CGRP does not play an important role in cardiovascular regulation under normal, resting conditions, although exogenous alpha-CGRP induces a marked, comparable vasorelaxation in different regional vascular beds.

摘要

外源性降钙素基因相关肽(CGRP)引起的血管活性反应程度在不同区域血管床之间是否存在差异尚不清楚。内源性CGRP在调节基础血管活性中是否发挥功能作用也不明确。为了解决这两个问题,对27只麻醉大鼠进行了实验,这些大鼠通过颈动脉流量探头和颈静脉、左心室(LV)及股动脉中的导管进行监测;还对6只清醒犬进行了实验,这些犬长期植入了LV压力计、主动脉和心房导管以及升主动脉、冠状动脉、颈动脉和肾流量探头。在这两个物种中,静脉注射人α-CGRP(0.1 - 0.5微克/千克)均可诱导剂量依赖性外周血管舒张,而用CGRP受体竞争性拮抗剂α-CGRP[8 - 37](30微克/千克/分钟,静脉注射)预处理可完全消除这种舒张作用。用放射性微球技术在大鼠中测量区域血流量显示,静脉注射α-CGRP(0.3微克/千克)引起的心脏血流量增加(+53±16%)比大脑血流量增加(+14±6%)更大(p < 0.05)。然而,在使用普萘洛尔进行β-肾上腺素能受体阻断的情况下,这两个血管床的血流量增加是相同的。在清醒犬中,静脉注射α-CGRP(0.3微克/千克)可使冠状动脉(+24±6%)、颈动脉(+26±3%)和肾血流量(+26±6%)产生相似的增加,这与其他血管扩张剂引起的模式不同;在平均动脉压和总外周阻力降低程度相同的情况下,α-CGRP引起的冠状动脉和颈动脉血流量增加明显少于腺苷或硝普钠(p < 0.05)。与α-CGRP不同,正如预期的那样,腺苷和硝普钠在这些血管床中引起了明显不同的血流量变化。在这两个物种中,给予药理学阻断剂量的α-CGRP[8 - 37]均未改变全身血流动力学或区域血流分布。因此,我们得出结论,内源性α-CGRP在正常静息条件下的心血管调节中不发挥重要作用,尽管外源性α-CGRP在不同区域血管床中可诱导显著且相当的血管舒张。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验